EPSILOGEN LTD

Active London

Other research and experimental development on natural sciences and engineering

21 employees website.com
Life sciences and medical technology Other research and experimental development on natural sciences and engineering
E

EPSILOGEN LTD

Other research and experimental development on natural sciences and engineering

Founded 26 Jul 2016 Active London, United Kingdom 21 employees website.com
Life sciences and medical technology Other research and experimental development on natural sciences and engineering

Previous Company Names

IGEM THERAPEUTICS LIMITED 26 Jul 2016 — 17 Apr 2020
Accounts Submitted 4 Oct 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 25 Jul 2025 Next due 8 Aug 2026 3 months remaining
Net assets £10M £3M 2024 year on year
Total assets £15M £529K 2024 year on year
Total Liabilities £5M £3M 2024 year on year
Charges 4
2 outstanding 2 satisfied

Contact & Details

Contact

Registered Address

Waterfront, Arc West London Manbre Road Hammersmith London W6 9RH United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for EPSILOGEN LTD (10295520), an active life sciences and medical technology company based in London, United Kingdom. Incorporated 26 Jul 2016. Other research and experimental development on natural sciences and engineering. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2017–2024)

Cash in Bank

£7.77M

Decreased by £1.12M (-13%)

Net Assets

£10.23M

Increased by £2.75M (+37%)

Total Liabilities

£4.52M

Decreased by £3.28M (-42%)

Turnover

N/A

Employees

21

Increased by 6 (+40%)

Debt Ratio

31%

Decreased by 20 (-39%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 4
Grants 4

Investors (9)

Investor NameInvestor SinceParticipating Rounds
Investor 3Jun 2017Series A, Series B
Investor 1Nov 2018Series A
Investor 2Nov 2018Series A

Share Capital

Share Capital

Share allotments and capital structure

19 Allotments 116,525,474 Shares £79.80m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
11 Aug 202512,965,867£10.75m£0.829
17 Jun 20252,883£0.288£0
7 Apr 20252,258£0.226£0
19 Mar 202532,706,544£27.12m£0.829
19 Mar 20251,630,610£1.35m£0.829

Officers

Officers

2 active 1 resigned
Status
Emma JohnsonDirectorBritishUnited Kingdom291 Feb 2023Active
Peter Michael FinanDirectorBritishEngland5831 Mar 2017Active

Shareholders

Shareholders (49)

British Patient Capital Limited
10.2%
11,415,257
Novartis Bioventures Ltd
9.3%
10,363,428

Persons with Significant Control

Persons with Significant Control (0)

0 Active 8 Ceased

Sophia Karagiannis

Ceased 31 Mar 2017

Ceased

Epidarex Capital Iii Uk, Lp

Ceased 15 Dec 2023

Ceased
Ceased

Alsa Uk Holdings Ltd

Ceased 28 Sept 2020

Ceased

Alek Safarian

Ceased 24 Feb 2022

Ceased

Epidarex Capital Ii, Lp

Ceased 15 Dec 2023

Ceased

Vivienne Frances Cox

Ceased 31 Mar 2017

Ceased

James Frederick Spicer

Ceased 31 Mar 2017

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

2 outstanding 2 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
10 Dec 2025OfficersTermination of Emma Johnson as director on 2025-12-10
4 Oct 2025AccountsAnnual accounts made up to 2024-12-31
18 Aug 2025CapitalAllotment of shares (GBP 12,452.5474) on 2025-08-11
25 Jul 2025Confirmation StatementConfirmation statement made on 2025-07-25 with updates
20 Jun 2025CapitalAllotment of shares (GBP 11,155.9607) on 2025-06-17
10 Dec 2025 Officers

Termination of Emma Johnson as director on 2025-12-10

4 Oct 2025 Accounts

Annual accounts made up to 2024-12-31

18 Aug 2025 Capital

Allotment of shares (GBP 12,452.5474) on 2025-08-11

25 Jul 2025 Confirmation Statement

Confirmation statement made on 2025-07-25 with updates

20 Jun 2025 Capital

Allotment of shares (GBP 11,155.9607) on 2025-06-17

Recent Activity

Latest Activity

Termination of Emma Johnson as director on 2025-12-10

4 months ago on 10 Dec 2025

Annual accounts made up to 2024-12-31

6 months ago on 4 Oct 2025

Allotment of shares (GBP 12,452.5474) on 2025-08-11

8 months ago on 18 Aug 2025

Confirmation statement made on 2025-07-25 with updates

9 months ago on 25 Jul 2025

Allotment of shares (GBP 11,155.9607) on 2025-06-17

10 months ago on 20 Jun 2025